Intact Protein Mass Spectrometry for Therapeutic Protein Quantitation, Pharmacokinetics, and Biotransformation in Preclinical and Clinical Studies: An Industry Perspective-Reference-Cited by-同舟云学术

Intact Protein Mass Spectrometry for Therapeutic Protein Quantitation, Pharmacokinetics, and Biotransformation in Preclinical and Clinical Studies: An Industry Perspective

Published:2020-09-01 Issue:8 Volume:32 Page:1886-1900
ISSN:1044-0305
Container-title:Journal of the American Society for Mass Spectrometry
language:en
Short-container-title:J. Am. Soc. Mass Spectrom.

Author:

Kellie John F.¹^ORCID,Tran John C.²^ORCID,Jian Wenying³^ORCID,Jones Barry⁴,Mehl John T.⁵,Ge Ying⁶^ORCID,Henion Jack⁷,Bateman Kevin P.⁸^ORCID

Affiliation:

1. Bioanalysis, Immunogenicity & Biomarkers, GlaxoSmithKline, Collegeville, Pennsylvania 19426, United States

2. Biochemical & Cellular Pharmacology, Genentech Inc., South San Francisco, California 94080, United States

3. DMPK, Janssen Research & Development, Johnson & Johnson, Spring House, Pennsylvania 19477, United States

4. Q Squared Solutions, 19 Brown Road, Ithaca, New York 14850, United States

5. Bioanalytical Research, Bristol-Myers Squibb, Princeton, New Jersey 08648, United States

6. Department of Cell and Regenerative Biology, Department of Chemistry, Human Proteomics Program, University of Wisconsin-Madison, Madison, Wisconsin 53706, United States

7. Advion, Inc., 61 Brown Road, Ithaca, New York 14850, United States

8. PPDM, Merck & Co., Inc., West Point, Pennsylvania 19486, United States

Funder

National Institute of General Medical Sciences

Publisher

American Chemical Society (ACS)

Subject

Spectroscopy,Structural Biology

Link

https://pubs.acs.org/doi/pdf/10.1021/jasms.0c00270

Reference110 articles.

1. Rituximab (IDEC-C2B8): Validation of a Sensitive Enzyme-Linked Immunoassay Applied to a Clinical Pharmacokinetic Study